к Opioids inhibit tumor angiogenesis by suppressing VEGF signaling
Open Access
- 14 November 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 3 (1), 3213
- https://doi.org/10.1038/srep03213
Abstract
Opioids are effective analgesics for the management of moderate to severe cancer pain. Here we show that κ opioid receptor (KOR) agonists act as anti-angiogenic factors in tumors. Treatment with KOR agonists, U50,488H and TRK820, significantly inhibited human umbilical vein endothelial cell (HUVEC) migration and tube formation by suppressing VEGFR2 expression. In contrast, treatment with a μ opioid receptor agonist, DAMGO, or a δ opioid receptor agonist, SNC80, did not prevent angiogenesis in HUVECs. Lewis lung carcinoma (LLC) or B16 melanoma grafted in KOR knockout mice showed increased proliferation and remarkably enhanced tumor angiogenesis compared with those in wild type mice. On the other hand, repeated intraperitoneal injection of TRK820 (0.1–10 μg/kg, b.i.d.) significantly inhibited tumor growth by suppressing tumor angiogenesis. These findings indicate that KOR agonists play an important role in tumor angiogenesis and this knowledge could lead to a novel strategy for cancer therapy.This publication has 25 references indexed in Scilit:
- The κ opioid system regulates endothelial cell differentiation and pathfinding in vascular developmentBlood, 2011
- Morphine Suppresses Tumor Angiogenesis through a HIF-1α/p38MAPK PathwayThe American Journal of Pathology, 2010
- Convergence of Notch and β-catenin signaling induces arterial fate in vascular progenitorsThe Journal of cell biology, 2010
- Systems Biology of Vascular Endothelial Growth FactorsMicrocirculation, 2008
- Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor GrowthCancer Cell, 2007
- VEGF receptor signalling ? in control of vascular functionNature Reviews Molecular Cell Biology, 2006
- Endogenous Inhibitors of AngiogenesisCancer Research, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971